Aptose Biosciences, Inc. (APTO) News
Filter APTO News Items
APTO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APTO News Highlights
- APTO's 30 day story count now stands at 2.
- Over the past 9 days, the trend for APTO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about APTO are CRC, NOV and PRI.
Latest APTO News From Around the Web
Below are the latest news stories about APTOSE BIOSCIENCES INC that investors may wish to consider to help them evaluate APTO as an investment opportunity.
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual MeetingReporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML PatientsTUS Single Agent and TUS/VEN Combination Demonstrate Favorable Safety and Tolerability TUS/VEN Combination Active Across Broad Populations of AML and Demonstrates 25% Complete Response Rate Among All-comers, including 20% CRc in Wildtype AML TUS Targets VEN Resistance Mechanisms, Enabling TUS/VEN Combination to Achieve Responses in Difficult-to-treat Pri |
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleSAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer. With a healthcare tenure of more than 25 years, Mr. Payne has held several CFO a |
Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call TranscriptAptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call Transcript November 9, 2023 Aptose Biosciences Inc. beats earnings expectations. Reported EPS is $-1.76, expectations were $-2.16. Operator: Good afternoon. My name is Hope, and I will be your conference operator today. I would like to welcome everyone to the Aptose Biosciences Conference Call for the Third […] |
Aptose Reports Results for the Third Quarter 2023Tuspetinib (TUS) Targets Venetoclax (VEN) Resistance MechanismsTUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated and Wildtype TUS/VEN Overall Response Rate of 48% in Heavily Pre-Treated Relapsed/Refractory AML Patients Tuspetinib Favorable Safety Profile Continues with TUS/VEN Doublet TherapyConference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences |
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingData from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML PatientsSAN DIEGO and TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that clinical data for tuspetinib, a once daily oral therapy, has been selected for oral presentation at the 65th American So |
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibTuspetinib (TUS) Combination with Venetoclax (VEN) Clinical Findings Highlighted TUS Targets VEN Resistance Mechanisms to Re-sensitize VEN Failure Patients to VEN44% ORR with TUS/VEN in Difficult-to-Treat VEN Failure R/R AML Patients48% ORR with TUS/VEN in Heavily Pre-treated R/R AML PatientsConsistent Favorable Safety with TUS Single Agent and TUS/VEN Doublet SAN DIEGO and TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a |
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date: Thursday, November 9, 2023 Time: 5:00 PM ETAudio Webcas |
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30thSAN DIEGO and TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Company will provide a clinical update on Monday, October 30, 2023 at 8:30 AM Eastern Time, in conjunction with poster presentations at the European School of Haematology (ESH) 6th International Conference |
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International ConferenceCompany to Hold Clinical Update Webcast; Details ForthcomingSAN DIEGO and TORONTO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that two abstracts on tuspetinib, Aptose’s Phase 1/2 myeloid kinase inhibitor in development for acute myeloid leukemia (AML), have been accepted for post |
Aptose to Present at the Cantor Global Healthcare ConferenceSAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City. Dr. William G. Rice, Chairman, President and CEO of Aptose, will part |